Tailoring Therapy to Individual Patients Paul D. Miller The pharmacological agents for the prevention and treatment of postmenopausal osteoporosis (PMO) registered with the Food and Drug Administration (FDA) are listed…
Determining Success of Therapy and What to Do When Therapy Fails Paul D. Miller Osteoporosis therapies are designed to improve bone strength and reduce the risk for fracture. When the…
Treatment Options Pauline M. Camacho The National Osteoporosis Foundation has outlined clinical recommendations regarding initiation of therapy for low bone mass and osteoporosis (Table 8.1). According to their guidelines, treatment…
Acquired Vitamin D Deficiency Pauline M. Camacho Epidemiology This chapter focuses on acquired vitamin D deficiency among adults. The prevalence of this condition has been reported to be as high…
Secondary Causes of Osteoporosis* Pauline M. Camacho Current therapies for osteoporosis are efficacious in reducing fractures and improving surrogate markers [i.e., bone mineral density (BMD) and bone markers]. Correctable factors…
Biochemical Evaluation Pauline M. Camacho Successful management of osteoporosis requires a careful choice of biochemical tests to determine the presence of secondary causes of osteoporosis. In addition, biochemical markers of…
Bone Densitometry: Using Dual-energy X-ray Absorptiometry for Monitoring Paul D. Miller Central dual-energy x-ray absorptiometry (DXA) has been the foundation for monitoring patients with osteoporosis. Monitoring is useful for following…
Assessment of Fracture Risk Paul D. Miller Use of Bone Mineral Density for Fracture Risk Assessment As pointed out in Chapter 1, the T-score has (and will remain) an important…
Pathogenesis Pauline M. Camacho Bone Remodeling Cycle Bone is in a constant state of turnover or activity throughout life. Remodeling is the process of renewing bone by breaking down old…
